DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Public ClinicalTrials.gov record NCT04920617. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Study identification
- NCT ID
- NCT04920617
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 102 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 17, 2021
- Primary completion
- Sep 30, 2024
- Completion
- Mar 31, 2025
- Last update posted
- Apr 6, 2023
2021 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Compassionate Cancer Care Medical Group | Fountain Valley | California | 92708 | Recruiting |
| Boca Raton Regional Hospital | Boca Raton | Florida | 33486 | Withdrawn |
| BRCR Medical Center Inc. | Hollywood | Florida | 33021 | Withdrawn |
| BRCR Medical Center Inc. | Plantation | Florida | 33322 | Withdrawn |
| Comprehensive Hematology and Oncology | St. Petersburg | Florida | 33709 | Withdrawn |
| Blood and Marrow Transplant Group of Georgia | Atlanta | Georgia | 30342 | Recruiting |
| Indiana University Health Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | Recruiting |
| Tulane Cancer Center Office of Clinical Research | New Orleans | Louisiana | 70112 | Recruiting |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | Recruiting |
| Christus St. Vincent Regional Cancer Center | Santa Fe | New Mexico | 87505 | Recruiting |
| Brody School of Medicine at East Carolina University | Greenville | North Carolina | 27834 | Recruiting |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | Withdrawn |
| University of Toledo Medical Center | Toledo | Ohio | 43614 | Withdrawn |
| Toledo Clinic Cancer Center | Toledo | Ohio | 43623 | Recruiting |
| Allegheny Health Network (AHN) West Penn Hospital | Pittsburgh | Pennsylvania | 15224 | Recruiting |
| Reading Hospital - McGlinn Cancer Institute | West Reading | Pennsylvania | 19611 | Recruiting |
| Prairie Lakes Health Care System | Watertown | South Dakota | 57201 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
Recently updated Refractory Diffuse Large B-cell Lymphoma trials
Other public records listing Refractory Diffuse Large B-cell Lymphoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07676877: Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Not yet recruiting
- NCT06649812: Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma Recruiting
- NCT05272384: Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma Recruiting
- NCT03321643: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma Active, not recruiting
- NCT01955499: Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Active, not recruiting
- NCT03038672: Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04920617, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2023 · Synced Aug 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04920617 live on ClinicalTrials.gov.